Difference between revisions of "Team:ETH Zurich/Achievements"
Line 21: | Line 21: | ||
<ul> | <ul> | ||
− | <li | + | <li>We completed the Judging Form</li> |
− | <li | + | <li>We created a <a href="https://2015.igem.org/Team:ETH_Zurich/Description">description of our project</a> in time and documented each aspect of the project on this page.</li> |
− | <li | + | <li>Documented 20 parts taken from the <a href="https://2015.igem.org/Team:ETH_Zurich/Parts"> Registry of Standard Biological Parts</a>.</li> |
</ul> | </ul> | ||
Line 39: | Line 39: | ||
<li>We implemented a method to do single cell analysis of cancer cells by <a href="https://2015.igem.org/Team:ETH_Zurich/Design#System_Overview">expressing Annexin V in the <i> E. coli</i> outer membrane</a>, which enables them to selectively bind to apoptotic cancer cells.</li> | <li>We implemented a method to do single cell analysis of cancer cells by <a href="https://2015.igem.org/Team:ETH_Zurich/Design#System_Overview">expressing Annexin V in the <i> E. coli</i> outer membrane</a>, which enables them to selectively bind to apoptotic cancer cells.</li> | ||
− | <li | + | <li>We designed 8 synthetic <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">LldR dependent promoters</a> and characterized them. Additionally, the influence of the lacate importer LldP was characterized.</li> |
− | <li | + | <li>We documented and submitted two new <a href="https://2015.igem.org/Team:ETH_Zurich/Basic_Part">basic parts</a> to the iGEM parts registry and created a <a href="https://2015.igem.org/Team:ETH_Zurich/Part_Collection">part collection</a> with 14 parts.</li> |
− | <li | + | <li>We characterized parts of the natural <i>E. coli</i> <a href="https://2015.igem.org/Team:ETH_Zurich/Results#Characterization_of_the_LldR_promoter">lldPRD-operon</a>, on which there is only a limited amount of information present in the Parts Registry and in the literature.</li> |
<li>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Chip">chip</a> for future application of our MicroBeacon <i>E. coli</i>.</li> | <li>We designed a <a href="https://2015.igem.org/Team:ETH_Zurich/Chip">chip</a> for future application of our MicroBeacon <i>E. coli</i>.</li> | ||
Line 58: | Line 58: | ||
<li>We separately modeled two different signals of our cancer detection system, the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">Lactate Module</a> and the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module"> AHL Module</a>.</li> | <li>We separately modeled two different signals of our cancer detection system, the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Lactate_Module">Lactate Module</a> and the <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/AHL_Module"> AHL Module</a>.</li> | ||
− | <li> We defined and estimated <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Parameters">all relevant parameters for our models</a>.</li> | + | <li>We defined and estimated <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Parameters">all relevant parameters for our models</a>.</li> |
<li>We integrated the two modules into a <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Single-cell_Model">Combined Compartment Model</a> to simulate a logical AND gate.</li> | <li>We integrated the two modules into a <a href="https://2015.igem.org/Team:ETH_Zurich/Modeling/Single-cell_Model">Combined Compartment Model</a> to simulate a logical AND gate.</li> | ||
Line 75: | Line 75: | ||
<ul> | <ul> | ||
− | <li | + | <li>We went to two different schools, thaught the children about what DNA is, performed experiments with them and published an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Awareness#_Newspaper_Articles_">article about it in the local newspaper</a>.</li> |
− | <li | + | <li>We told the ETH-student magacine <a href="http://www.vseth.ethz.ch/polykum/archiv#2014/2015">polykum</a> about iGEM and gave an interview.</li> |
− | <li | + | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Stockholm">collaborated</a> with the team from <a href="https://2015.igem.org/Team:Stockholm"> Stockholm</a> by testing some of their constructs.</li> |
− | <li | + | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Amoy">contributed</a> to the <a href="http://issuu.com/amoy-igem/docs/2015newsletterno1?e=17843433/13214508">Newsletters</a> from <a href="https://2015.igem.org/Team:Amoy#">Amoys team</a>, met with the <a href="https://2015.igem.org/Team:TU_Darmstadt">Darmstadt team</a>, helped with a survey from <a href="https://2015.igem.org/Team:EPF_Lausanne">EPFL</a> and provided <a href="https://2015.igem.org/Team:Uniandes_Colombia">Colombias team</a> with protocols and <a href="https://2015.igem.org/Team:ETH_Zurich/Collaborations#Colombia">advice</a> when their transformations did not work.</li> |
− | <li | + | <li>We <a href="https://2015.igem.org/Team:ETH_Zurich/Practices">interviewed many different experts</a> from various fields, such as <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Medicine">medical doctors</a>, <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Ethics">somebody from the ethics commission</a>, the <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Business">founder of a start-up</a> or an <a href="https://2015.igem.org/Team:ETH_Zurich/Practices/Patents">expert in patents law</a> and <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Influence_of_human_practices">integrated the advice and ideas</a> we got from them into the <a href="https://2015.igem.org/Team:ETH_Zurich/Design#Design">design</a>.</li> |
</ul> | </ul> | ||
<p></p> | <p></p> |
Revision as of 09:38, 18 September 2015
- Project
- Modeling
- Lab
- Human
Practices - Parts
- About Us
Achievements
We are proud to announce that we achieved the following goals
General Achievements
- We completed the Judging Form
- We created a description of our project in time and documented each aspect of the project on this page.
- Documented 20 parts taken from the Registry of Standard Biological Parts.
Experimental Achievements
- We designed a novel system for detection of circulating tumour cells in blood samples using genetically modified bacteria.
- We designed a genetic circuit that integrates two different cancer specific signals (lactate and AHL)in an AND gate.
- We implemented a method to do single cell analysis of cancer cells by expressing Annexin V in the E. coli outer membrane, which enables them to selectively bind to apoptotic cancer cells.
- We designed 8 synthetic LldR dependent promoters and characterized them. Additionally, the influence of the lacate importer LldP was characterized.
- We documented and submitted two new basic parts to the iGEM parts registry and created a part collection with 14 parts.
- We characterized parts of the natural E. coli lldPRD-operon, on which there is only a limited amount of information present in the Parts Registry and in the literature.
- We designed a chip for future application of our MicroBeacon E. coli.
- We participated in the interlab study.
- Our experiments complied with the safety instructions at the Department of Biosystems Science and Engineering D-BSSE in Basel where our lab is situated.
Modeling Achievements
- We separately modeled two different signals of our cancer detection system, the Lactate Module and the AHL Module.
- We defined and estimated all relevant parameters for our models.
- We integrated the two modules into a Combined Compartment Model to simulate a logical AND gate.
- To account for the diffusion and degradation of signaling molecules under real-world conditions we designed various Reaction-diffusion Models.
- We optimized our model by integrating experimental data gathered by the characterization of our LldR promoter constructs.
- We showed that the successful detection of cancer cells with our system is feasible in principle.
Human Practices Achievements
- We went to two different schools, thaught the children about what DNA is, performed experiments with them and published an article about it in the local newspaper.
- We told the ETH-student magacine polykum about iGEM and gave an interview.
- We collaborated with the team from Stockholm by testing some of their constructs.
- We contributed to the Newsletters from Amoys team, met with the Darmstadt team, helped with a survey from EPFL and provided Colombias team with protocols and advice when their transformations did not work.
- We interviewed many different experts from various fields, such as medical doctors, somebody from the ethics commission, the founder of a start-up or an expert in patents law and integrated the advice and ideas we got from them into the design.
Medal Criteria
We registered for iGEM, had a great summer so far, and now we are looking forward to attending the Giant Jamboree! | Going for it! | |
We completed and submitted the Judging Form | ||
We created a description of our project in time. | ||
We documented all the parts taken from the Registry of Standard Biological Parts | ||
We are going to present a poster and give a talk at the Giant Jamboree. | Going for it! | |
We created this website for you to learn about every aspect of our iGEM project. | ||
We documented and submitted two new basic parts to the iGEM parts registry and created a part collection with 14 parts. | ||
Experimentally validate that at least one new BioBrick Part of your own design | ||
These new parts we also submitted to the iGEM Parts Registry. | ||
Human Practices in iGEM. Demonstrate how your team has identified, investigated and addressed one or more of these issues in the context of your project. | ||
Expand on your silver medal Human Practices activity | ||
Help another university to characterize a part | ||
Improve the characterization of a previously existing BioBrick Part or Device |